Tiotropium Bromide

• CAT Number: I001398
• CAS Number: 136310-93-5
• Molecular Formula: C19H22BrNO4S2
• Molecular Weight: 472.42
• Purity: ≥95%
• Synonyms: [(1S,2S,4R,5R)-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonan-7-yl] 2-hydroxy-2,2-dithiophen-2-ylacetate;bromide
• InChI: InChI=1S/C19H22NO4S2.BrH/c1-20(2)12-9-11(10-13(20)17-16(12)24-17)23-18(21)19(22,14-5-3-7-25-14)15-6-4-8-26-15;/h3-8,11-13,16-17,22H,9-10H2,1-2H3;1H/q+1;/p-1/t11?,12-,13+,16-,17+
• InChIKey: DQHNAVOVODVIMG-RGECMCKFSA-M
• SMILES: C[N+]1([C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)C(C4=CC=CS4)(C5=CC=CS5)O)C.[Br-]

Tiotropium bromide（Cat No.:I001398）is a long-acting anticholinergic bronchodilator with the molecular formula C19H22BrNO4S2, used primarily to manage chronic obstructive pulmonary disease (COPD) and asthma. It works by selectively blocking muscarinic M3 receptors in airway smooth muscle, leading to prolonged bronchodilation and improved airflow. Administered via inhalation, usually once daily, tiotropium provides sustained symptom relief and reduces exacerbation frequency. It is well-tolerated, with dry mouth being the most common side effect. Tiotropium enhances lung function, exercise tolerance, and quality of life in patients with chronic respiratory diseases. Regular use supports long-term disease control.

Reference

[1]. Barnes PJ. Tiotropium bromide. Expert Opin Investig Drugs. 2001 Apr;10(4):733-40.
[Content Brief]

[2]. ZuWallack AR, ZuWallack RL. Tiotropium bromide, a new, once-daily inhaled anticholinergic bronchodilator for chronic-obstructive pulmonary disease. Expert Opin Pharmacother. 2004 Aug;5(8):1827-35.
[Content Brief]

[3]. Lipson DA. Tiotropium bromide. Int J Chron Obstruct Pulmon Dis. 2006;1(2):107-14.
[Content Brief]

[4]. Mamary AJ, Criner GJ. Tiotropium bromide for chronic obstructive pulmonary disease. Expert Rev Respir Med. 2009 Jun;3(3):211-20.
[Content Brief]

[5]. Szmidt M. [The influence of treatment with formoterol, formoterol with tiotropium, formoterol with inhaled glucocorticosteroid and tiotropium on lung functions, tolerance of exercise and simple, morning everyday activities in patients with chronic obstructive pulmonary disease (COPD)]. Pneumonol Alergol Pol. 2012;80(3):255-62.
[Content Brief]